Latest Adrenoleukodystrophy Stories
GULF SHORES, Ala., April 29, 2014 /PRNewswire/ -- If successful, Neuralgene's (http://www.neuralgene.com) PRCN-323 treatment
GAITHERSBURG, Md., May 18 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis." In this program, Lentigen will collaborate with Dr.
University of Alberta medical researchers have made a major breakthrough in understanding a group of deadly disorders that includes the disease made famous in the movie Lorenzo's Oil.
The ELA Association represents the largest funder for research on this fatal brain disease.
A strategy that combines gene therapy with blood stem cell therapy may be a useful tool for treating a fatal brain disease, French researchers have found.
The Stop ALD Foundation today applauded the investigators who are reporting in the current issue of Science successful results from the pioneering use of gene therapy for adrenoleukodystrophy (ALD), a potentially crippling and fatal brain disorder in young boys.
Aldagen, a biopharmaceutical company, has received orphan drug designation for ALD-101 from the FDA.
Aldagen, Inc. today announced that it has received orphan drug designation for ALD-101 from the U.S. Food and Drug Administration (FDA).
Use of Lorenzo's Oil in young boys who have been diagnosed with but are not yet showing signs of a pediatric neurological disorder known as X-linked adrenoleukodystrophy (X-ALD) may prevent the disease from developing in the body.
- A volcanic mudflow.